STOCK TITAN
  1. Home
  2. News
  3. LUNG

Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 4, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 6696232. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for lung disease. The Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform, are designed to assess and treat patients with severe emphysema/COPD who despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com


Stock LUNG logo
Pulmonx Corporation

NASDAQ:LUNG

LUNG Rankings

#3328 Ranked by Market Cap
#4263 Ranked by Stock Gains
N/A Ranked by Dividends

LUNG Latest News

May 6, 2024
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 1, 2024
Pulmonx Reports First Quarter 2024 Financial Results
Apr 10, 2024
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
Apr 2, 2024
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Mar 15, 2024
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LUNG Stock Data

347.40M
36.98M
4.17%
92.86%
2.9%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About LUNG

pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company’s first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp